Valle Venia presents new song by LPS feat. Lara: Where will it take me
27.2.2026 10:15:00 CET | news aktuell GmbH | Press Release

The song describes the challenge of trusting the flow, relying on oneself, following one's own values with confidence.
In a time when everything seems to begin to dissolve, when disorientation prevails more than ever
and when one is searching for something to hold on to, certainty can be found in uncertainty.
Lara's authentic interpretation, with her multi-faceted voice, conveys confidence in finding a way for oneself and others.
In the faceless, noisy crowd, where glances are not returned and touches are not felt, one is pulled away by an invisible hand.
You are on your own, but somewhere there is a light and a hope that guides you when the fog lifts and you find yourself
in the certainty of meeting someone who “can read my mind and my soul.”
Invisibly connected, across time and space, this path is open.
Contacts
Press contactValle Venia art & science
press@valle-venia.comImages

Links
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Vyoma awarded ESA data procurement contract for space-based data on small space debris24.2.2026 10:57:08 CET | Press Release
Munich, February 24th, 2026 – Vyoma, a Munich-based company providing Space Domain Awareness (SDA) capabilities, has been selected as the winner of the ESA tender on ”Data Procurement for Space-Based Statistical Data on Small Space Debris Phase 1”, funded via ESA‘s Space Safety Programme (S2P).
Medi-Globe Launches mAI Companion® — the World’s First Real Time AI Assistant for Pancreatic EUS, Co Developed with IHU Strasbourg —Now MDR CE Marked and Available for Clinical Use in Europe24.2.2026 10:00:00 CET | Press Release
Rohrdorf (Achenmühle), Germany — February 24, 2026 — Medi-Globe today announced the launch of mAI Companion®, a real-time medical AI solution designed to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS) — addressing one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically change patient outcomes.
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 08:25:47 CET | Press Release
Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.
Clean energy needs a clean planet: PLAN-B NET ZERO and everwave launch joint initiative20.2.2026 13:26:45 CET | Press Release
Berlin - A strong start to 2026. PLAN-B NET ZERO enters into a partnership with the Aachen-based environmental scale-up everwave. With the guiding principle ‘1 euro = 1 kilogram of waste’, the partners recovered 10,000 kilograms of waste from rivers in Cambodia at the start of the initiative.
Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 11:16:12 CET | Press Release
Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom